Health Care & Life Sciences » Biotechnology | Changzhou Qianhong Bio-Pharma Co. Ltd.

Changzhou Qianhong Bio-Pharma Co. Ltd. A | Cash Flow

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
181,689.10
242,155.90
262,292.00
224,683.50
174,909.10
211,044.90
Depreciation, Depletion & Amortization
21,795.20
21,667.40
21,033.20
27,317.90
63,088.90
63,383.30
Other Funds
-
556.50
4,049.70
-
2,270.60
25,582.40
Funds from Operations
212,241.20
262,078.70
277,792.50
250,409.50
284,216.50
296,285.80
Changes in Working Capital
51,982.50
10,041.20
8,711.60
43,958.80
66,661.30
136,439
Net Operating Cash Flow
160,258.70
252,037.50
286,504.10
206,450.70
217,555.20
159,846.80
Capital Expenditures
127,592.40
90,526.20
215,775.30
138,935.20
87,626.60
Sale of Fixed Assets & Businesses
0.20
16.00
4.90
27.10
54.50
Purchase/Sale of Investments
609,976.60
522,588.20
247,642.10
52,014.90
46,246.10
Net Investing Cash Flow
737,318.80
611,698.40
449,472.60
201,674.50
38,592.00
Cash Dividends Paid - Total
80,000.00
80,000.00
96,000.00
96,000.00
101,897.70
Issuance/Reduction of Debt, Net
5,000.00
23,000.00
279,000.00
66,000.00
11,318.60
Net Financing Cash Flow
75,000.00
57,556.50
178,950.30
30,000.00
133,308.00
Net Change in Cash
657,844.40
416,323.60
21,052.00
20,115.40
39,522.70
Free Cash Flow
32,666.30
161,511.30
70,728.70
67,515.50
129,928.60
Deferred Taxes & Investment Tax Credit
399.50
2,609.80
9,209.70
674.70
20.30
3,724.80
Net Assets from Acquisitions
-
-
8,500.00
18,071.50
-
Other Sources
250.00
1,400.00
22,440.00
7,320.00
2,734.00
Change in Capital Stock
-
-
-
-
44,999.50
Exchange Rate Effect
5,784.40
893.80
5,070.30
5,108.40
6,132.50

About Changzhou Qianhong Bio-Pharma Co.

View Profile
Address
No. 518 Yunhe Road
Changzhou Jiangsu 213125
China
Employees -
Website http://www.qhsh.com.cn
Updated 07/08/2019
Changzhou Qianhong Biopharma Co., Ltd. engages in the research and development, production, and sale of bio-pharmaceutical products. It focuses on polysaccharides and enzymes. Its business scope covers lyophilized powder for injections, small volume parenteral solutions, tablets, hard capsules, granules, and active pharmaceutical ingredient (API) products.